<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954187</url>
  </required_header>
  <id_info>
    <org_study_id>59070</org_study_id>
    <nct_id>NCT00954187</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy</brief_title>
  <official_title>Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To compare the efficacy of oral gabapentin and its newer analogue pregabalin in
      postoperative pain control after photorefractive keratectomy (PRK).

      Methods: One hundred and four patients who meet the inclusion criteria undergoing PRK in one
      or both eyes will be randomized into one of two treatment groups. Those in group A will be
      treated with gabapentin, and those in group B will be treated with pregabalin to control
      postoperative PRK pain. Patients in both groups will begin treatment two hours prior to
      surgery in order to achieve therapeutic blood levels of each medication. After surgery the
      patients will assess their pain level using the visual analogue scale (VAS) at different
      intervals of time - one hour after surgery, the evening of the surgery, and three times each
      day for three subsequent days. Patients will also daily assess their level of somnolence
      using the Epworth Sleepiness Scale (ESS) and record the presence of dizziness for the same
      amount of time. On the fourth day they will return to clinic for a postoperative appointment.
      At that time the pain, sleepiness, and dizziness assessment scales will be collected and
      analyzed. The patients will return one month later to further assess long-term pain and
      healing after PRK.

      Results: Both gabapentin and pregabalin have been shown in previous studies to treat
      postoperative pain effectively. The effects of gabapentin 300 mg TID for 3 days versus
      pregabalin 50 mg TID for 3 days on decreasing overall postoperative pain following PRK will
      be presented.

      Conclusion: The effectiveness of the two different treatment medications will be analyzed,
      and the conclusion will be based on the results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODS:

      One hundred and four patients who meet the inclusion criteria undergoing photorefractive
      keratectomy (PRK) in one or both eyes will be randomly assigned into one of two treatment
      groups via computer. Those in group A will be treated with gabapentin and those in group B
      will be treated with pregabalin to control postoperative PRK pain. Patients in both groups
      will begin treatment two hours prior to surgery. Patients in the gabapentin group will take
      300 mg three times a day starting two hours prior to surgery and will continue for a total of
      four days. Patients in the pregabalin group will take 50 mg three times a day starting two
      hours prior to surgery and will also continue for four days.

      Only the refractive surgery coordinator and the patient will know what medication the patient
      is taking. The patient will be instructed not to share this information with any other study
      participants or their surgeon. The coordinator will keep a list of the patients ID numbers
      and the treatments they are receiving.

      Prior to surgery, each patient will be taught how to assess their pain level using the visual
      analogue scale (VAS), a well documented method of pain assessment. After surgery the patients
      will assess their pain levels at different intervals of time - one hour after surgery, the
      evening of the surgery, and three times a day for four subsequent days. Patients will also
      daily assess their level of somnolence using the Epworth Sleepiness Scale (ESS) and record
      the presence of dizziness daily for the same amount of time. On the fourth day they will
      return to clinic for a post operative appointment. At that time the pain assessment scales
      will be collected and analyzed. The patients will return at one month to further assess long
      term pain after PRK.

      Statistical Analysis:

      Postoperative pain levels recorded using the visual analogue scales, ESS, and self reported
      dizziness assessments will be collected on the fourth postoperative day. These will be
      compiled into data sets and analyzed. Data will be compiled into means with lower and upper
      quartiles and analyzed using a two-sided t test. The difference in pain levels will be
      described throughout the postoperative period to determine if one medication significantly
      reduces postoperative pain initially within the first 24 hours, during the interval between
      24 hours to four days, and further after surgery (one month postoperatively). Data regarding
      levels of somnolence and dizziness will also be reported.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased Overall Pain Score as Measured by the Visual Analogue Scale</measure>
    <time_frame>one month</time_frame>
    <description>No data was collected or analyzed. No study procedures were performed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neurontin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyrica</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>50 mg PO TID</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Undergoing PRK in at least one eye

        Exclusion Criteria:

          -  Serious medical problems within the last 6 months including myocardial infarction
             (heart attack), congestive heart failure, stroke, deep vein thrombosis, pulmonary
             embolism, and other conditions, etc.

          -  Serious kidney disease as evidenced by the need for dialysis or kidney transplant.

          -  History of seizure or other neurologic disorders.

          -  Patients intending to become pregnant or who are pregnant or nursing over the
             projected course of treatment.

          -  Currently taking gabapentin or pregabalin for other medical purposes.

          -  Known allergic reaction to gabapentin or pregabalin from previous use.

          -  Plans to move out of the area within 8 weeks after the surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Narvaez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University - Ophthalmology</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shortt AJ, Allan BD. Photorefractive keratectomy (PRK) versus laser-assisted in-situ keratomileusis (LASIK) for myopia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005135. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD005135.</citation>
    <PMID>16625626</PMID>
  </reference>
  <reference>
    <citation>Ambrósio R Jr, Wilson S. LASIK vs LASEK vs PRK: advantages and indications. Semin Ophthalmol. 2003 Mar;18(1):2-10. Review.</citation>
    <PMID>12759854</PMID>
  </reference>
  <reference>
    <citation>Lee JB, Kim JS, Choe C, Seong GJ, Kim EK. Comparison of two procedures: photorefractive keratectomy versus laser in situ keratomileusis for low to moderate myopia. Jpn J Ophthalmol. 2001 Sep-Oct;45(5):487-91.</citation>
    <PMID>11583670</PMID>
  </reference>
  <reference>
    <citation>Van de Pol C, Greig JL, Estrada A, Bissette GM, Bower KS. Visual and flight performance recovery after PRK or LASIK in helicopter pilots. Aviat Space Environ Med. 2007 Jun;78(6):547-53.</citation>
    <PMID>17571652</PMID>
  </reference>
  <reference>
    <citation>Walker MB, Wilson SE. Recovery of uncorrected visual acuity after laser in situ keratomileusis or photorefractive keratectomy for low myopia. Cornea. 2001 Mar;20(2):153-5.</citation>
    <PMID>11248818</PMID>
  </reference>
  <reference>
    <citation>Sandoval HP, de Castro LE, Vroman DT, Solomon KD. Refractive Surgery Survey 2004. J Cataract Refract Surg. 2005 Jan;31(1):221-33.</citation>
    <PMID>15721716</PMID>
  </reference>
  <reference>
    <citation>Hazelrigg SR, Auer JE, Seifert PE. Experience in 100 transthoracic balloon pumps. Ann Thorac Surg. 1992 Sep;54(3):528-32.</citation>
    <PMID>1510521</PMID>
  </reference>
  <reference>
    <citation>Dirks J, Fredensborg BB, Christensen D, Fomsgaard JS, Flyger H, Dahl JB. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology. 2002 Sep;97(3):560-4.</citation>
    <PMID>12218520</PMID>
  </reference>
  <reference>
    <citation>Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg. 2002 Oct;95(4):985-91, table of contents.</citation>
    <PMID>12351281</PMID>
  </reference>
  <reference>
    <citation>Pandey CK, Navkar DV, Giri PJ, Raza M, Behari S, Singh RB, Singh U, Singh PK. Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study. J Neurosurg Anesthesiol. 2005 Apr;17(2):65-8.</citation>
    <PMID>15840990</PMID>
  </reference>
  <reference>
    <citation>Turan A, Karamanlioğlu B, Memiş D, Hamamcioglu MK, Tükenmez B, Pamukçu Z, Kurt I. Analgesic effects of gabapentin after spinal surgery. Anesthesiology. 2004 Apr;100(4):935-8.</citation>
    <PMID>15087630</PMID>
  </reference>
  <reference>
    <citation>Turan A, Memiş D, Karamanlioğlu B, Yağiz R, Pamukçu Z, Yavuz E. The analgesic effects of gabapentin in monitored anesthesia care for ear-nose-throat surgery. Anesth Analg. 2004 Aug;99(2):375-8, table of contents.</citation>
    <PMID>15271709</PMID>
  </reference>
  <reference>
    <citation>Ménigaux C, Adam F, Guignard B, Sessler DI, Chauvin M. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg. 2005 May;100(5):1394-9, table of contents.</citation>
    <PMID>15845693</PMID>
  </reference>
  <reference>
    <citation>Kavalieratos CS, Dimou T. Gabapentin therapy for painful, blind glaucomatous eye: case report. Pain Med. 2008 Apr;9(3):377-8. doi: 10.1111/j.1526-4637.2006.00167.x.</citation>
    <PMID>18366517</PMID>
  </reference>
  <reference>
    <citation>Poujois A, Vidailhet M, Trocello JM, Bourdain F, Gaymard B, Rivaud-Péchoux S. Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy. Eur J Neurol. 2007 Sep;14(9):1060-2.</citation>
    <PMID>17718702</PMID>
  </reference>
  <reference>
    <citation>Rahman W, Proudlock F, Gottlob I. Oral gabapentin treatment for symptomatic Heimann-Bielschowsky phenomenon. Am J Ophthalmol. 2006 Jan;141(1):221-2.</citation>
    <PMID>16387013</PMID>
  </reference>
  <reference>
    <citation>Choudhuri I, Sarvananthan N, Gottlob I. Survey of management of acquired nystagmus in the United Kingdom. Eye (Lond). 2007 Sep;21(9):1194-7. Epub 2006 May 26.</citation>
    <PMID>16732211</PMID>
  </reference>
  <reference>
    <citation>Nissman SA, Tractenberg RE, Babbar-Goel A, Pasternak JF. Oral gabapentin for the treatment of postoperative pain after photorefractive keratectomy. Am J Ophthalmol. 2008 Apr;145(4):623-629. doi: 10.1016/j.ajo.2007.11.012. Epub 2008 Jan 28.</citation>
    <PMID>18226799</PMID>
  </reference>
  <reference>
    <citation>Agarwal A, Gautam S, Gupta D, Agarwal S, Singh PK, Singh U. Evaluation of a single preoperative dose of pregabalin for attenuation of postoperative pain after laparoscopic cholecystectomy. Br J Anaesth. 2008 Nov;101(5):700-4. doi: 10.1093/bja/aen244. Epub 2008 Aug 20.</citation>
    <PMID>18716003</PMID>
  </reference>
  <reference>
    <citation>Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin--calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009 Mar;142(1-2):13-6. doi: 10.1016/j.pain.2008.11.019. Epub 2009 Jan 6. Review.</citation>
    <PMID>19128880</PMID>
  </reference>
  <reference>
    <citation>Guay DR. Pregabalin in neuropathic pain: a more &quot;pharmaceutically elegant&quot; gabapentin? Am J Geriatr Pharmacother. 2005 Dec;3(4):274-87. Review.</citation>
    <PMID>16503325</PMID>
  </reference>
  <reference>
    <citation>Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004 Dec 14;63(11):2104-10.</citation>
    <PMID>15596757</PMID>
  </reference>
  <reference>
    <citation>Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005 Apr;6(4):253-60.</citation>
    <PMID>15820913</PMID>
  </reference>
  <reference>
    <citation>Huskisson EC. Measurement of pain. Lancet. 1974 Nov 9;2(7889):1127-31.</citation>
    <PMID>4139420</PMID>
  </reference>
  <reference>
    <citation>Scott J, Huskisson EC. Graphic representation of pain. Pain. 1976 Jun;2(2):175-84.</citation>
    <PMID>1026900</PMID>
  </reference>
  <reference>
    <citation>Revill SI, Robinson JO, Rosen M, Hogg MI. The reliability of a linear analogue for evaluating pain. Anaesthesia. 1976 Nov;31(9):1191-8.</citation>
    <PMID>1015603</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <results_first_submitted>September 18, 2014</results_first_submitted>
  <results_first_submitted_qc>September 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2014</results_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>Neurontin
Gabapentin: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days</description>
        </group>
        <group group_id="P2">
          <title>Pregabalin</title>
          <description>Lyrica
pregabalin: 50 mg PO TID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No subjects were assigned treatment and no study procedures were performed</participants>
                <participants group_id="P2" count="0">No subjects were assigned treatment and no study procedures were performed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No subjects were randomized and assigned treatment so Baseline Characteristics were not collected</population>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>Neurontin
Gabapentin: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days</description>
        </group>
        <group group_id="B2">
          <title>Pregabalin</title>
          <description>Lyrica
pregabalin: 50 mg PO TID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Gender</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decreased Overall Pain Score as Measured by the Visual Analogue Scale</title>
        <description>No data was collected or analyzed. No study procedures were performed.</description>
        <time_frame>one month</time_frame>
        <population>No subjects were assigned treatment and no study procedures were performed</population>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Neurontin
Gabapentin: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin</title>
            <description>Lyrica
pregabalin: 50 mg PO TID</description>
          </group>
        </group_list>
        <measure>
          <title>Decreased Overall Pain Score as Measured by the Visual Analogue Scale</title>
          <description>No data was collected or analyzed. No study procedures were performed.</description>
          <population>No subjects were assigned treatment and no study procedures were performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>Neurontin
Gabapentin: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days</description>
        </group>
        <group group_id="E2">
          <title>Pregabalin</title>
          <description>Lyrica
pregabalin: 50 mg PO TID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julio Narvaez, MD</name_or_title>
      <organization>Loma Linda University</organization>
      <phone>9095589408</phone>
      <email>thamilton@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

